2024
Daily glucose variability is associated with intrahepatic fat content, β cell sensitivity, and biomarkers of glycolysis in youth with obesity
Barbieri E, Bonet J, Fox D, Nelson R, Nelson M, Nelson L, Fernandez C, Van Name M, Samuels S, Caprio S, Sabati M, Galderisi A, Sherr J, Man C, Santoro N. Daily glucose variability is associated with intrahepatic fat content, β cell sensitivity, and biomarkers of glycolysis in youth with obesity. Obesity 2024, 33: 116-124. PMID: 39658509, PMCID: PMC11666407, DOI: 10.1002/oby.24175.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBiomarkersBlood GlucoseChildFemaleGlucose Tolerance TestGlycolysisHumansInsulinInsulin ResistanceInsulin-Secreting CellsLiverMagnetic Resonance ImagingMalePediatric ObesityConceptsIntrahepatic fat contentDaily glucose variabilityLiver proton density fat fractionProton density fat fractionGlucose variabilityInsulin sensitivityOral glucose tolerance testFat fractionInsulin secretionAssociated with insulin resistanceFirst-phase insulin secretionAssociated with 2-h glucoseGlucose tolerance testGlucose standard deviationMagnetic resonance imagingOral minimal modelCoefficient of variationBasal insulin secretionPediatric obesityPostprandial glucoseTolerance testCell sensitivityInsulin resistanceObesityResonance imaging
2016
The long-term treatment of a patient with type 1 diabetes mellitus and glutaric aciduria type 1: the effect of insulin
Del Rizzo M, Galderisi A, Celato A, Furlan F, Giordano L, Cazzorla C, Fasan I, Moretti C, Zschocke J, Burlina A. The long-term treatment of a patient with type 1 diabetes mellitus and glutaric aciduria type 1: the effect of insulin. European Journal Of Pediatrics 2016, 175: 1123-1128. PMID: 26847429, DOI: 10.1007/s00431-016-2699-5.Peer-Reviewed Case Reports and Technical NotesConceptsType 1 diabetes mellitusGlutaric aciduria type 1Diabetes mellitusType 1Metabolic disordersInsulin daily doseIrreversible neuronal damageLong-term treatmentSimilar pathogenic mechanismsDifferent metabolic disordersBilateral striatal necrosisMonths of ageEffect of insulinAcute hypotoniaClassical T1DMLimb dystoniaNeurological outcomeInfective episodesNeuronal injuryDaily doseNeuronal damageDystonic movementsHypoglycemic episodesCarnitine supplementationGlycemic profile
2015
Cardiac Autoimmunity as a Novel Biomarker, Mediator, and Therapeutic Target of Heart Disease in Type 1 Diabetes
Lipes M, Galderisi A. Cardiac Autoimmunity as a Novel Biomarker, Mediator, and Therapeutic Target of Heart Disease in Type 1 Diabetes. Current Diabetes Reports 2015, 15: 30. PMID: 25821130, PMCID: PMC4376963, DOI: 10.1007/s11892-015-0598-1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnimalsAutoimmunityBiomarkersDiabetes Mellitus, Type 1Heart DiseasesHumansMagnetic Resonance ImagingMyocardiumConceptsCardiovascular diseaseHeart diseaseChronic myocardial inflammationPoor CVD outcomesUnderstanding of CVDType 1 diabetesCardiac autoimmunityMicrovascular complicationsCVD outcomesMyocardial inflammationClinical evidenceHeart syndromeExcess mortalityClinical studiesNovel biomarkersT1DTherapeutic implicationsTherapeutic targetType 2Type 1Same diseaseT2D.DiseaseDiagnostic assaysT1D.